Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Persistence of Immunity in 4-year-old Children Previously Immunised With IPV-Al AJV (Picovax®)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Children that have been vaccinated with IPV-Al AJV in the VIPV-07 and VIPV-07 E1 trials and have completed these trials~2. Healthy, as assessed from medical history and physical examination~3. Parent(s)/guardian(s), according to the local legal requirements, have been properly informed about the trial and have signed the informed consent form~4. Parent(s)/guardian(s), according to the local legal requirements, have been granted access to the child´s trial related medical records~5. Parent(s)/guardian(s), according to the local legal requirements, are likely to comply with trial procedures~Exclusion Criteria:~1. Previous vaccination with OPV~2. Previous vaccination with IPV outside the VIPV-07 and VIPV-07 E1 trials~3. Known or suspected immunodeficiency (e.g. leukaemia, lymphoma) or family history of congenital or hereditary immunodeficiency. HIV is not an exclusion criterion.~4. Severe uncontrolled chronic (e.g. neurologic, pulmonary, gastrointestinal, hepatic, renal or endocrine) disease~5. Known or suspected allergy to vaccine constituents (e.g. hypersensitivity to formaldehyde and/or 2-phenoxy-ethanol)~6. Uncontrolled coagulopathy or blood disorder contraindicating intramuscular injections or blood sampling~7. Treatment with a product which is likely to modify the immune response (e.g. blood products and immunoglobulins) prior to inclusion or planned during the trial period~8. Participating in another interventional clinical trial~9. Not suitable for inclusion in the opinion of the investigator

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 4 Years
- Healthy Volunteers: t

Study Arms:
- IPV-Al AJV (Type: EXPERIMENTAL): One dose of 0.5 mL of IPV-Al AJV injected intramuscularly perpendicular to the skin in the RIGHT deltoid muscle.

Based on this trial design, predict the completion outcome and termination type (if applicable).